<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04733924</url>
  </required_header>
  <id_info>
    <org_study_id>NT/200803/SENSORIL/URT</org_study_id>
    <nct_id>NCT04733924</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability of Sensoril® in Improving Immunity and Thereby Reducing Incidence of Upper Respiratory Tract Infections</brief_title>
  <official_title>Efficacy and Tolerability of Sensoril® in Improving Immunity and Thereby Reducing Incidence of Upper Respiratory Tract Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vedic Lifesciences Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vedic Lifesciences Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      to assess the efficacy and safety of a standardized Withania somnifera extract (Sensoril®) as&#xD;
      an immunomodulator in individuals suffering from recurrent URTIs. The study population will&#xD;
      be administered with this unique blend of WS extract for 12 weeks and will be assessed as per&#xD;
      the study designated efficacy and safety variables.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Actual">September 23, 2021</completion_date>
  <primary_completion_date type="Actual">April 29, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wisconsin Upper Respiratory Symptom Survey-21</measure>
    <time_frame>screening to day 0 and day 57 to day 84</time_frame>
    <description>the effect of IP consumption on incidence of upper respiratory tract infection (URTI) episodes till day 28, 56, and 85 in comparison to placebo as assessed by Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Immune Health</condition>
  <arm_group>
    <arm_group_label>Withania somnifera 125 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule before breakfast for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Withania somnifera 250 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule before breakfast for 84 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microcrystalline Cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One capsule before breakfast for 84 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aqueous extract of roots plus leaves of Withania somnifera 125 mg</intervention_name>
    <description>One capsule before breakfast for 84 days</description>
    <arm_group_label>Withania somnifera 125 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aqueous extract of roots plus leaves of Withania somnifera 250 mg</intervention_name>
    <description>One capsule before breakfast for 84 days</description>
    <arm_group_label>Withania somnifera 250 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Microcrystalline Cellulose</intervention_name>
    <description>One capsule before breakfast for 84 days</description>
    <arm_group_label>Microcrystalline Cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females aged ≥18 to ≤ 50 years.&#xD;
&#xD;
          2. High susceptibility to URTIs, defined as ≥ 4 URTI episodes within 12 months.&#xD;
&#xD;
          3. Presence of an active URTI episode (Defined as a score of ≥5 for atleast 2 of&#xD;
             following 6 symptoms: runny nose, plugged nose, sneezing, sore throat, scratchy&#xD;
             throat, or cough on the WURSS-21 assessment), with onset of symptoms within 48 hours&#xD;
             prior to screening.&#xD;
&#xD;
          4. SpO2 ≥ 96% as assessed by fingertip pulse oximetry&#xD;
&#xD;
          5. Commitment to adhere to former diet and physical activities throughout the study&#xD;
             period. 6. Able to comply and perform the procedures requested by the protocol&#xD;
             (consumption of study medications, filling daily eDiary for health updates, biological&#xD;
             sample collection procedures and study visit schedule) 7. Participants who are&#xD;
             literate enough to understand the essence of study, are informed about the purpose of&#xD;
             the study, and understand their rights. 8. Participants who are able to give written&#xD;
             informed consent and are willing to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of rhinitis medicamentosa, anatomical nasal obstruction or deformity, nasal&#xD;
             reconstructive surgery, etc.&#xD;
&#xD;
          2. Clinical signs or Symptoms indicating lower respiratory tract infection.&#xD;
&#xD;
          3. Known sensitivity to the investigational product or any excipients of the drug&#xD;
             product.&#xD;
&#xD;
          4. Any clinically significant abnormalities of the upper respiratory tract (such as&#xD;
             stridor, laryngomalacia, etc.)&#xD;
&#xD;
          5. Any clinically significant acute or chronic respiratory illness (such as Sinusitis,&#xD;
             pharyngitis/tonsillitis, etc.)&#xD;
&#xD;
          6. Chronic cough of any origin not accompanied to other symptoms of URTI&#xD;
&#xD;
          7. Unable to abstain from any home-based remedies for common cold such as steam&#xD;
             inhalation, decoctions, vapour rub, etc. throughout the study period.&#xD;
&#xD;
          8. Presence of uncontrolled type 2 diabetes (Indicated by fasting blood glucose (FBG)&#xD;
             ≥126 mg/dL)&#xD;
&#xD;
          9. Presence of uncontrolled hypertension (Defined as Systolic Blood Pressure (SBP) ≥ 140&#xD;
             mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 90 mm Hg).&#xD;
&#xD;
         10. Participants with abnormal liver and kidney function tests, defined as:&#xD;
&#xD;
               -  Serum aspartate aminotransferase (AST) and alanine transaminase (ALT) levels &gt;&#xD;
                  1.5 × upper level of normal&#xD;
&#xD;
               -  Serum alkaline phosphatase (ALP) levels &gt; 1.5 × upper level of normal&#xD;
&#xD;
               -  Serum creatinine levels &gt; 1.5 × upper level of normal&#xD;
&#xD;
         11. Unable to abstain from ginger, avocado, soy or other known dietary supplements for&#xD;
             common cold throughout the study period.&#xD;
&#xD;
         12. Vaccination against influenza or swine flu within 3 months prior to screening.&#xD;
&#xD;
         13. Those who have taken or will be taking or are taking antibiotics, antivirals,&#xD;
             steroids, nasal decongestants, antihistamines, or other medications that are expected&#xD;
             to alleviate cold symptoms within two weeks prior to randomization.&#xD;
&#xD;
         14. History of any significant neurological and psychiatric condition which may affect the&#xD;
             participation and inference of the study's end points.&#xD;
&#xD;
         15. Individuals having a history (in past 2 years) of smoking or currently smoking or&#xD;
             using any form of smokeless tobacco.&#xD;
&#xD;
         16. Participation in other clinical trials in last 90 days prior to screening&#xD;
&#xD;
         17. Participants with heavy alcohol consumption, defined as&#xD;
&#xD;
               -  For men: More than 14 standard alcoholic drink (SAD)/week or more than 4 SAD in a&#xD;
                  day.&#xD;
&#xD;
               -  For women: More than 7 SAD/week or more than 3 SAD in a day. (NOTE - A standard&#xD;
                  alcoholic drink contains approximately 14 grams of alcohol, which is equivalent&#xD;
                  to 12 ounces of beer (~5% alcohol), 8.5 ounces of malt liquor (~9% alcohol), 5&#xD;
                  ounces of wine (~12% alcohol), 3.5 ounces of fortified wine (e.g., sherry or&#xD;
                  port), or 1.5 ounces of liquor (distilled spirits; ~40% alcohol).&#xD;
&#xD;
         18. Binge drinkers, defined as 4 or more SAD for women, and 5 or more SAD for men, in a&#xD;
             2-hour time frame.&#xD;
&#xD;
         19. History or presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)&#xD;
             infection.&#xD;
&#xD;
         20. Participants who have clinically significant following severe illness (i.e.,&#xD;
             Cardiovascular, endocrine system, immune system, respiratory system, hepatobiliary&#xD;
             system, kidney and urinary system, neuropsychiatric, musculoskeletal, inflammatory,&#xD;
             blood and tumors, gastrointestinal diseases, etc.)&#xD;
&#xD;
         21. Females who are pregnant/planning to be pregnant/lactating or taking any oral&#xD;
             contraceptives.&#xD;
&#xD;
         22. Any condition that could, in the opinion of the investigator, preclude the&#xD;
             participant's ability to successfully and safely complete the study or that may&#xD;
             confound study outcomes.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr. Rajesh Kewalramani Clinic</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>40068</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanjivani Day Care and Ayurved Center,</name>
      <address>
        <city>Palghar</city>
        <state>Maharashtra</state>
        <zip>401 305</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care N Cure Multispeciality Hospital</name>
      <address>
        <city>Thāne</city>
        <state>Maharashtra</state>
        <zip>401209</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

